

- a Dutch survey among breast cancer patients and oncological professionals. *Asia Pac J Oncol Nurs*. 2015;2:35-41.
89. Harrison S, Sinclair R. Optimal management of hair loss (alopecia) in children. *Am J Clin Dermatol*. 2003;4:757-770.
  90. Beisecker A, Cook MR, Ashworth J, et al. Side effects of adjuvant chemotherapy: perceptions of node-negative breast cancer patients. *Psychooncology*. 1997;6:85-93.
  91. Reid EE, Haley AC, Borovicka JH, et al. Clinical severity does not reliably predict quality of life in women with alopecia areata, telogen effluvium, or androgenic alopecia. *J Am Acad Dermatol*. 2012;66:e97-e102.
  92. Smith K, Winstanley J, Boyle F, O'Reilly A, White M, Antill Y. Madarosis: a qualitative study to assess perceptions and experience of Australian patients with early breast cancer treated with taxane-based chemotherapy. *Support Care Cancer*. 2018;26:483-489.
  93. Nangia J, Wang T, Osborne C, et al. Effect of a scalp cooling device on alopecia in women undergoing chemotherapy for breast cancer: the SCALP randomized clinical trial. *JAMA*. 2017;317:596-605.
  94. Rugo HS, Melin SA, Voigt J. Scalp cooling with adjuvant/neoadjuvant chemotherapy for breast cancer and the risk of scalp metastases: systematic review and meta-analysis. *Breast Cancer Res Treat*. 2017;163:199-205.
  95. Freites-Martinez A, Chan D, Sibaud V, et al. Assessment of quality of life and treatment outcomes of patients with persistent postchemotherapy alopecia. *JAMA Dermatology*. <https://doi.org/10.1001/jamadermatol.2018.5071>. Published online March 6, 2019.
  96. Rozner RN, Freites-Martinez A, Shapiro J, et al. Safety of Salpha-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies. *Breast Cancer Res Treat*. 2019;174:15-26.
  97. Heidelbaugh JJ. Endocrinology update: hirsutism. *FP Essent*. 2016;451:17-24.
  98. Kaune KM, Haas E, Jantke M, et al. Successful Nd:YAG laser therapy for hair removal in the oral cavity after plastic reconstruction using hairy donor sites. *Dermatology*. 2013;226:324-328.
  99. Balter S, Hopewell JW, Miller DL, Wagner LK, Zelefsky MJ. Fluoroscopically guided interventional procedures: a review of radiation effects on patients' skin and hair. *Radiology*. 2010;254:326-341.
  100. Balana ME, Charreau HE, Leiros GJ. Epidermal stem cells and skin tissue engineering in hair follicle regeneration. *World J Stem Cells*. 2015;7:711-727.
  101. Chueh SC, Lin SJ, Chen CC, et al. Therapeutic strategy for hair regeneration: hair cycle activation, niche environment modulation, wound-induced follicle neogenesis, and stem cell engineering. *Exp Opin Biol Ther*. 2013;13:377-391.
  102. Morris CL, Stinnett S, Woodward J. The role of bimatoprost eyelash gel in chemotherapy-induced madarosis: an analysis of efficacy and safety. *Int J Trichology*. 2011;3:84-91.
  103. Chen SC, Huang BS, Lin CY, et al. Psychosocial effects of a skin camouflage program in female survivors with head and neck cancer: a randomized controlled trial. *Psychooncology*. 2017;26:1376-1383.
  104. Huang S, Liu HE. Effectiveness of cosmetic rehabilitation on the body image of oral cancer patients in Taiwan. *Support Care Cancer*. 2008;16:981-986.
  105. Bolduc C, Sperling LC, Shapiro J. Primary cicatricial alopecia: Lymphocytic primary cicatricial alopecias, including chronic cutaneous lupus erythematosus, lichen planopilaris, frontal fibrosing alopecia, and Graham-Little syndrome. *J Am Acad Dermatol*. 2016;75:1081-1099.

---

## Answers to CME examination

Identification No. JB0519

May 2019 issue of the Journal of the American Academy of Dermatology.

Freites-Martinez A, Shapiro J, van den Hurk C, Goldfarb S, Jimenez JJ, Rossi AM, Paus R, Lacouture ME.  
*J Am Acad Dermatol* 2019;80:1199-213.

1. e  
2. a

3. c  
4. a